Management of transfusional iron overload in Latin America: Current outlook and expert panel recommendations

Hematology

Volumn 14, Issue 1, 2009, Pages 22-32

  Araújo, Aderson ^a   Drelichman, Guillermo ^b   Cançado, Rodolfo D ^c   Watman, Nora ^d   Magalhães, Silvia M M ^e   Duhalde, Mauricio ^f   Marfil, Javier ^g   Feliú, Aurora ^h   Clementina, Landolfi ⁱ   Ballesteros, Adriana Linares ^j   di Stefano, Marco ^k   Angulo, Ivan ^l   Fattori, André ^l   Figueiredo, Stella ^l   Friedrich, João ^l   Pereira, Fabrício ^l   Peña, Jorge ^l   Barrero, Alberto ^l   Guerrero, Susan ^l   Gutiérrez Espíndola, Guillermo ^l   Rojas, Victor Salinas ^l   Soto, Janet ^l   Boyd, Jaime ^l   Joly, Rafael ^l   Sergio, Murillo ^l   de Soyano, Aixa Müller ^l   Pérez Bández, Olimpia ^l   Plumacher, Zaída ^l   more..

^a Fundacao Hemope   (Brazil)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^f CLÍNICA LAS CONDES   (Chile)

^g HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^h HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

ⁱ Ministerio del Poder Popular para el Trabajo y Seguridad Social Venezuela   (Venezuela)

^j UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^k Hospital de Clinicas Caracas   (Venezuela)

^l NONE

more..

Author keywords

Blood transfusions; Haemosiderosis; Iron chelators; Iron overload

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; HEMOGLOBIN;

AGRANULOCYTOSIS; ALLERGIC REACTION; ALLOIMMUNIZATION; APLASTIC ANEMIA; ARTHRALGIA; ARTHROPATHY; ARTICLE; AUTOIMMUNITY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEARING DISORDER; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; INJECTION SITE REACTION; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LIVER HEMOSIDEROSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGISTER; SICKLE CELL ANEMIA; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; THALASSEMIA MAJOR; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; NEWBORN; REVIEW;

HUMANS; INFANT, NEWBORN; IRON OVERLOAD; LATIN AMERICA;

EID: 64949196097     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X385179     Document Type: Article

References (59)

1. Cancado R, Angulo I, Plumacher Z,MorenoM, Linares A, Zarate JP. Latin American registry of patients (pts) with transfusional hemosiderosis (Th): The RELATH study. Blood 2007; 110: Abstract 4013.
2. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 2001: 47-61.
3. Cazzola M, De Stefano P, Ponchio L et al. Relationship between transfusion regimen and suppression of erythropoiesis in betathalassaemia major. Br J Haematol 1995; 89: 473-478
4. Cazzola M, Borgna-Pignatti C, Locatelli F et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37: 135-140.
5. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-252.
6. Harmatz P, Butensky E, Quirolo K et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76-79.
7. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
8. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236.
9. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
10. Olivieri NF, Nathan DG, MacMillan JH et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-578.
11. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia. Available at: http://www.thalassaemia.org.cy/Publications.htm (accessed 30 May 2008).
12. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004; 364: 1343-1360.
13. Vichinsky E. Consensus document for transfusion-related iron overload. Semin Hematol 2001; 38 (1 Suppl. 1): S2-S4.
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™. Myelodysplastic syndromes. V.2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ mds.pdf (accessed 30 May 2008).
15. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200.
16. Gattermann N, Porter J, Lopes LF, Seymour JF. Consensus statement on iron overload in myelodysplastic syndromes. Hematology Oncol Clin N Am 2005; 19 (Suppl. 1): S8-S25.
17. Jansen AJ, Essink-Bot ML, Beckers EA et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003; 121: 270-274.
18. Hellström-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin Hematol 2005; 42 (2 Suppl. 1): S10-S13.
19. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353: 1135-1146.
20. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004; 10: 1611-1626.
21. Brittenham GM, Badman DG; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-19.
22. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Herschko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504-1510.
23. Cappellini MD, Cohen A, Piga A et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelators, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
24. Gandon Y, Olivié D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-362.
25. St Pierre TG, Clark PR, Chua-anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861.
26. FerriScan. Information for clinicians. Available at: http://www.resonancehealth.com/ferriscan/ClinicianInfo (accessed 30May 2008).
27. 2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179.
28. 2*cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-355.
29. Voskaridou E, Douskou M, Terpos E et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br JHaematol 2004; 126: 736-742.
30. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-269.
31. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichnisky E. Thalassemia. ASH Educational Session 2004. Hematology 2004; 2004: 14-34.
32. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-287.
33. Daar S, Taher A, Pathare A et al. Deferasirox (Exjade, ICL670) provides 24-hour protection from labile plasma iron (LPI), in iron overloaded β-thalassaemia patients previously chelated with monoor combination therapy. Haematologica 2006; 91 (Suppl. 1): Abstract 0031.
34. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006; 107: 3436-3441.
35. Brittenham GM, Griffith PM, Nienhuis AW et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573
36. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2052.
37. Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: Results from a literature review. Health Qual Life Outcomes 2006; 4: 73.
38. Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 2007; 47: 1919-1929.
39. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24.
40. Kattamis A, Ladis V, Berdousi H et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: A 12-month trial. Blood Cells Mol Dis 2006; 36: 21-25.
41. Tanner MA, Galanello R, Dessi CSmith GC et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884.
42. Al-Refaie FN, Hershko C, Hoffbrand AV et al. Results of longterm deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224-229.
43. Nisbet-Brown E, Olivieri NF, Giardina PJ et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
44. Vichinsky E, Onyekwere O, Porter J et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-508.
45. Galanello R, Piga A, Forni GL et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343-1351.
46. Gattermann N, Cazzola M, Greenberg P et al. The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload. Leuk Res 2005; 29 (Suppl. 1): S67.
47. Exjade. Product information, Novartis Europharm Limited, 2006. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/exjade/ H-670-PI-en.pdf (accessed 30 May 2008).
48. Cappellini MD, Bejaoui M, Agaoglu L et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007; 29: 909-917.
49. Desferal (deferoxamine mesylate for injection USP). Prescribing information, Novartis Pharmaceuticals Corporation, November 2007. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/ desferal.pdf (accessed 30 May 2008).
50. Ferriprox. Product information, Apotex Europe B.V, 2004. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Ferriprox/ H-236-PI-en.pdf (accessed 30 May 2008).
51. Exjade (deferasirox). Prescribing information, Novartis Pharmaceuticals Corporation, December 2007. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf (accessed 30 May 2008).
52. Hershko C. Oral iron chelators: New opportunities and new dilemmas. Haematologica 2006; 91: 1307-1312.
53. Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880.
54. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008; 111: 583-587.
55. Altes A, Remacha AF, Sarda P et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007; 86: 443-447.
56. Altès A, Remacha AF, Sureda A et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 987-989.
57. Armand P, Kim HT, Cutler CS et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588
58. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ. Abnormal liver function tests following bone marrow transplantation: Aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol 2004; 16: 157-162.
59. Mahindra A, Sobecks R, Rybicki L et al. Elevated ferritin is associated with poorer survival following nonablative allogeneic transplantation. Blood 2007; 110: Abstract 606.